CXCR4 receptor as a promising target for oncolytic drugs

Yan Lavrovsky; Yan A Ivanenkov; Konstantin V Balakin; Darya A Medvedeva; Alexandre V Ivachtchenko

doi:10.2174/138955708785909907

CXCR4 receptor as a promising target for oncolytic drugs

Mini Rev Med Chem. 2008 Oct;8(11):1075-87. doi: 10.2174/138955708785909907.

Authors

Yan Lavrovsky¹, Yan A Ivanenkov, Konstantin V Balakin, Darya A Medvedeva, Alexandre V Ivachtchenko

Affiliation

¹ Small Molecule Drug Discovery, ChemDiv, Inc., San Diego, California 92121, USA.

PMID: 18855724
DOI: 10.2174/138955708785909907

Abstract

There has been considerable in vivo evidence that chemokine receptor CXCR4 and its endogenous ligand CXCL12 modulate some important physiological and pathophysiological processes, including cancer metastasis, angiogenesis, invasion, growth and progression. In this review we elucidate key aspects of CXCL12-CXCR4 signaling system with emphasis on peptide-based and small-molecule CXCR4 inhibitors.

Publication types

Review

MeSH terms

Animals
Antineoplastic Agents / chemistry
Antineoplastic Agents / pharmacology*
Antineoplastic Agents / therapeutic use
Chemokine CXCL12 / metabolism
Drug Design
Humans
Neoplasms / drug therapy*
Neoplasms / metabolism
Neoplasms / pathology*
Peptides / chemistry
Peptides / pharmacology
Peptides / therapeutic use
Receptors, CXCR4 / antagonists & inhibitors*
Receptors, CXCR4 / metabolism

Substances

Antineoplastic Agents
Chemokine CXCL12
Peptides
Receptors, CXCR4